Some anti‐lung cancer medicines like Pabosini can activate the Rb pathway and increase the expression of Meg3 in A549 and SK‐MES‐1 lung cancer cells, which provides a potential method for the treatment of lung cancer.3 Therefore, tumour‐suppressing lncRNAs have potential clinical application in the treatment of NSCLC. Here, MEG3 is linked to lung carcinoma.